Literature DB >> 19483649

Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

Seagal Teitz-Tennenbaum1, Qiao Li, Mary A Davis, Kari Wilder-Romans, Janet Hoff, Mu Li, Alfred E Chang.   

Abstract

Treatment of C57BL/6 mice with cyclophosphamide (100 mg/kg) and fludarabine (200 mg/kg) induced nonmyeloablative lymphodepletion without inhibiting D5 melanoma tumor growth. Using this model, we found that induction of lymphopenia before adoptive transfer of ex vivo anti-CD3/CD28 activated and interleukin-2 expanded D5-G6 tumor draining lymph node cells enhanced the antitumor efficacy of the infused cells in both pulmonary metastases and subcutaneous D5 bearing mice. However, induction of lymphopenia did not promote intratumoral or extratumoral proliferation or accumulation of the infused cells. We have previously shown that radiotherapy enhances the therapeutic efficacy of intratumoral unpulsed dendritic cell vaccination in subcutaneous murine tumor models by augmenting the induction of antitumor cellular immune responses. Here, we confirmed this finding in a murine metastatic melanoma liver tumor model. Furthermore, local tumor irradiation combined with intratumoral dendritic cell administration significantly enhanced the therapeutic efficacy of tumor-reactive T cell adoptive transfer in this lymphodepleted liver tumor model. This was evident by reduced liver tumor size, decreased incidence of spontaneous intra-abdominal metastasis, and prolonged survival, resulting in 46% of mice cured. This enhanced antitumor activity was associated with a selective increase in proliferation, accumulation, and function of CD4+ rather than CD8+ infused cells. This multimodality regimen may have translational applications for the treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483649      PMCID: PMC2743975          DOI: 10.1097/CJI.0b013e3181a95165

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  50 in total

Review 1.  Hepatic T cells and liver tolerance.

Authors:  Ian Nicholas Crispe
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

2.  Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.

Authors:  Qiao Li; Bo Yu; Amelia C Grover; Xianying Zeng; Alfred E Chang
Journal:  J Immunother       Date:  2002 Jul-Aug       Impact factor: 4.456

3.  A new ultrasound instrument for in vivo microimaging of mice.

Authors:  F S Foster; M Y Zhang; Y Q Zhou; G Liu; J Mehi; E Cherin; K A Harasiewicz; B G Starkoski; L Zan; D A Knapik; S L Adamson
Journal:  Ultrasound Med Biol       Date:  2002-09       Impact factor: 2.998

4.  Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

Authors:  Ruth Ganss; Eduard Ryschich; Ernst Klar; Bernd Arnold; Günter J Hämmerling
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.

Authors:  Scott E Strome; Stephen Voss; Ryan Wilcox; Tamekia L Wakefield; Koji Tamada; Dallas Flies; Andrei Chapoval; Jun Lu; Jan L Kasperbauer; Douglas Padley; Richard Vile; Dennis Gastineau; Peter Wettstein; Lieping Chen
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

6.  Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.

Authors:  Alfred E Chang; Qiao Li; Guihua Jiang; Theodoros N Teknos; Douglas B Chepeha; Carol R Bradford
Journal:  Head Neck       Date:  2003-03       Impact factor: 3.147

7.  Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis.

Authors:  Protul Shrikant; Matthew F Mescher
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

8.  T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Authors:  Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

9.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

10.  T cells compete for access to antigen-bearing antigen-presenting cells.

Authors:  R M Kedl; W A Rees; D A Hildeman; B Schaefer; T Mitchell; J Kappler; P Marrack
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  17 in total

Review 1.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

2.  Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.

Authors:  Sheinei J Saleem; Rebecca K Martin; Johanna K Morales; Jamie L Sturgill; David R Gibb; Laura Graham; Harry D Bear; Masoud H Manjili; John J Ryan; Daniel H Conrad
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

3.  Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.

Authors:  Eileen M Higham; Ching-Hung Shen; K Dane Wittrup; Jianzhu Chen
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

Review 4.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

5.  Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

Authors:  Maciej Kujawski; Chunyan Zhang; Andreas Herrmann; Karen Reckamp; Anna Scuto; Michael Jensen; Jiehui Deng; Stephen Forman; Robert Figlin; Hua Yu
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

6.  Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.

Authors:  Shuang Wei; Martin U Egenti; Seagal Teitz-Tennenbaum; Weiping Zou; Alfred E Chang
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

7.  Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.

Authors:  J Liu; J Li; Y Fan; K Chang; X Yang; W Zhu; X Wu; Yan Pang
Journal:  Ir J Med Sci       Date:  2014-05-30       Impact factor: 1.568

8.  Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice.

Authors:  Sungjune Kim; Rupal Ramakrishnan; Sergio Lavilla-Alonso; Prakash Chinnaiyan; Nikhil Rao; Erin Fowler; John Heine; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2014-06-19       Impact factor: 6.968

9.  Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

Authors:  Mohamed L Salem; Sabry A El-Naggar; David J Cole
Journal:  Cell Immunol       Date:  2009-12-05       Impact factor: 4.868

10.  In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.

Authors:  Chunqing Guo; Huanfa Yi; Xiaofei Yu; Daming Zuo; Jie Qian; Gary Yang; Barbara A Foster; John R Subjeck; Xiaolei Sun; Ross B Mikkelsen; Paul B Fisher; Xiang-Yang Wang
Journal:  Mol Cancer Ther       Date:  2012-08-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.